uproleselan

Uproleselan is a synthetic, glycomimetic small molecule and first-in-class E-selectin antagonist. It is designed to disrupt the interaction between E-selectin (CD62E), an adhesion molecule expressed on endothelial cells in the bone marrow and vasculature, and its ligands on leukemic myeloid cells. By blocking this interaction, uproleselan prevents leukemia cells from being sequestered in protective bone marrow microenvironments that promote chemoresistance and survival. This mechanism may sensitize leukemia cells to chemotherapy, reduce toxicity to normal tissues such as the gastrointestinal tract by limiting inflammatory cell activation, and potentially decrease thrombotic events by interfering with leukocyte-endothelial interactions[3][5][9]. Uproleselan is under investigation for use in acute myeloid leukemia (AML), particularly in relapsed/refractory disease as well as newly diagnosed elderly patients fit for intensive chemotherapy.

Brand names

uproleselan

Other names

Uproleselan sodiumGMI1271GMI-1271GMI 1271